Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model.

Authors

Francois Ricordeau, Sebastien Arthaud, Leila Langbour, Silvia Melzi, Aurelie Richard-Mornas, Hannah Doudoux, Benjamin Rolland, Laure Peter-Derex, Christelle Peyron

Published in

Annals of neurology. Aug 28, 2026. Epub Aug 28, 2026.

Abstract

Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34-year-old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning intranasal ketamine, with symptom recurrence upon discontinuation. To confirm this observation, ketamine was compared with vehicle in a crossover study in orexin knockout mice implanted for polysomnography. Ketamine dramatically reduced time spent in cataplexy (-76%, p = 0.008) without affecting sleep architecture. These translational findings suggest ketamine as a potential anticataplectic agent, warranting further clinical investigation. ANN NEUROL 2026.

PMID:
42663325
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.